• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.

作者信息

Kornbluth A

机构信息

Mt. Sinai Medical Center, New York, New York 10128, USA.

出版信息

Inflamm Bowel Dis. 1998 Nov;4(4):328-9. doi: 10.1002/ibd.3780040415.

DOI:10.1002/ibd.3780040415
PMID:9836088
Abstract
摘要

相似文献

1
Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.英夫利昔单抗获批用于克罗恩病：一份关于美国食品药品监督管理局胃肠病咨询委员会会议的报告。
Inflamm Bowel Dis. 1998 Nov;4(4):328-9. doi: 10.1002/ibd.3780040415.
2
Anti-TNF antibody approved for Crohn's disease.
Am J Health Syst Pharm. 1998 Oct 15;55(20):2073. doi: 10.1093/ajhp/55.20.2073.
3
Remicade approved for children with Crohn's disease.类克获批用于治疗克罗恩病患儿。
FDA Consum. 2006 Jul-Aug;40(4):6.
4
TNF inhibitors for Crohn's disease: when, which, and for how long.用于克罗恩病的肿瘤坏死因子抑制剂：何时使用、使用哪种以及使用多久。
Med Lett Drugs Ther. 2013 Dec 23;55(1432):102-3.
5
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
6
FDA advisers endorse natalizumab for Crohn's disease.美国食品药品监督管理局顾问批准那他珠单抗用于治疗克罗恩病。
Am J Health Syst Pharm. 2007 Sep 15;64(18):1886, 1888, 1890. doi: 10.2146/news070080.
7
The comeback kid: TYSABRI now FDA approved for Crohn disease.东山再起者：泰萨比（TYSABRI）现已获美国食品药品监督管理局批准用于治疗克罗恩病。
J Clin Invest. 2008 Mar;118(3):825-6. doi: 10.1172/JCI35179.
8
Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.英夫利昔单抗：关于其在克罗恩病和类风湿性关节炎中应用的最新综述
BioDrugs. 2002;16(2):111-48. doi: 10.2165/00063030-200216020-00005.
9
Infliximab: new indication. Severe Crohn's disease in children: many unknowns.
Prescrire Int. 2008 Aug;17(96):145.
10
Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients.儿童克罗恩病的早期抗肿瘤坏死因子治疗。基于人群的新诊断患者队列中临床结局的预测因素。
Scand J Gastroenterol. 2014 Dec;49(12):1425-31. doi: 10.3109/00365521.2014.966316. Epub 2014 Oct 13.

引用本文的文献

1
Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems.生物类似药与炎症性肠病的生物疗法：使用药物递送系统的挑战与靶向策略
Clin Exp Med. 2025 Apr 5;25(1):107. doi: 10.1007/s10238-025-01558-6.
2
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.用于炎症性肠病的治疗性抗体的免疫原性：治疗与临床考量
Drugs. 2025 Jan;85(1):67-85. doi: 10.1007/s40265-024-02115-3. Epub 2024 Nov 13.
3
Worldwide research trends in Crohn's disease treatment over the past 2 decades: a bibliometric analysis.
过去20年全球克罗恩病治疗的研究趋势：一项文献计量分析
Front Pharmacol. 2024 Oct 8;15:1441785. doi: 10.3389/fphar.2024.1441785. eCollection 2024.
4
Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems.炎症性肠病管理的进展：从传统治疗到单克隆抗体及未来的药物递送系统
Pharmaceutics. 2024 Sep 7;16(9):1185. doi: 10.3390/pharmaceutics16091185.
5
Surgical management of duodenal crohn's disease.十二指肠克罗恩病的外科治疗。
Langenbecks Arch Surg. 2024 Apr 19;409(1):132. doi: 10.1007/s00423-024-03324-w.
6
Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development.炎症性肠病患者生物治疗因抗药抗体产生导致的免疫原性及疗效丧失
Antibodies (Basel). 2024 Feb 26;13(1):16. doi: 10.3390/antib13010016.
7
Perianal fistulizing Crohn's disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies.肛周瘘管型克罗恩病：关于诊断、监测及管理的当前观点，重点关注新兴疗法
Indian J Gastroenterol. 2024 Feb;43(1):48-63. doi: 10.1007/s12664-024-01524-2. Epub 2024 Feb 3.
8
The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn's disease in real world-data: a retrospective study.真实世界数据中生物制剂与常规治疗相比对克罗恩病无手术生存的长期影响：一项回顾性研究。
BMC Gastroenterol. 2023 Dec 14;23(1):438. doi: 10.1186/s12876-023-03074-x.
9
Paradoxical Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor-Induced Psoriasis: A Systematic Review of Pathogenesis, Clinical Presentation, and Treatment.矛盾性肿瘤坏死因子-α（TNF-α）抑制剂诱导的银屑病：发病机制、临床表现及治疗的系统评价
Cureus. 2023 Aug 1;15(8):e42791. doi: 10.7759/cureus.42791. eCollection 2023 Aug.
10
Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study.英夫利昔单抗加速输注安全性和耐受性在炎症性肠病患者中不劣于标准输注方案：一项随机对照研究
Crohns Colitis 360. 2023 May 3;5(3):otad022. doi: 10.1093/crocol/otad022. eCollection 2023 Jul.